NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
17. Februar 2023 08:00 ET
|
NurExone
TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy...